Compare ATYR & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | CHMI |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | 59 | 14 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 98.5M |
| IPO Year | N/A | N/A |
| Metric | ATYR | CHMI |
|---|---|---|
| Price | $0.79 | $2.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $4.20 | $3.00 |
| AVG Volume (30 Days) | ★ 1.0M | 188.8K |
| Earning Date | 03-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.60% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $59.20 |
| P/E Ratio | ★ N/A | $139.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $2.17 |
| 52 Week High | $7.29 | $3.58 |
| Indicator | ATYR | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 58.14 |
| Support Level | $0.67 | $2.52 |
| Resistance Level | $0.85 | $2.76 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.89 | 76.65 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.